Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Champions Oncology (CSBR) Gross Profit (2016 - 2026)

Champions Oncology has reported Gross Profit over the past 17 years, most recently at $13.9 million for Q1 2026.

  • Quarterly results put Gross Profit at $13.9 million for Q1 2026, down 8.8% from a year ago — trailing twelve months through Jan 2026 was $44.2 million (down 29.65% YoY), and the annual figure for FY2025 was $28.6 million, down 33.73%.
  • Gross Profit for Q1 2026 was $13.9 million at Champions Oncology, up from $13.0 million in the prior quarter.
  • Over the last five years, Gross Profit for CSBR hit a ceiling of $29.1 million in Q2 2024 and a floor of $4.2 million in Q1 2024.
  • Median Gross Profit over the past 5 years was $11.6 million (2022), compared with a mean of $11.2 million.
  • Peak annual rise in Gross Profit hit 265.3% in 2025, while the deepest fall reached 82.52% in 2025.
  • Champions Oncology's Gross Profit stood at $12.6 million in 2022, then decreased by 22.28% to $9.8 million in 2023, then crashed by 38.01% to $6.1 million in 2024, then soared by 115.1% to $13.0 million in 2025, then increased by 6.57% to $13.9 million in 2026.
  • The last three reported values for Gross Profit were $13.9 million (Q1 2026), $13.0 million (Q4 2025), and $12.1 million (Q3 2025) per Business Quant data.